Table 2 Summary of safety data, gastrointestinal disorders with an incidence of 5% in any group and all psychiatric disorders in year 1

From: Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide

 

Placebo n=98

Liraglutide

Orlistat n=95

  

1.2 mg n=95

1.8 mg n=90

2.4 mg n=93

3.0 mg n=93

 
 

N (%) E

N (%) E

N (%) E

N (%) E

N (%) E

N (%) E

Summary of safety data

 Overall withdrawal ratea

24 (25)

17 (18)

20 (22)

27 (29)

18 (19)

28 (30)

 Participants with AEs

87 (88.8) 374

88 (92.6) 362

84 (93.3) 430

88 (94.6) 485

89 (95.7) 492

89 (93.7) 372

 Participants with any SAE

3 (3.1) 3

2 (2.1) 2

7 (7.8) 7

4 (4.3) 5

7 (7.5) 10

2 (2.1) 2

 Withdrawals due to AEs

3 (3.1) 7

5 (5.3) 12

6 (6.7) 10

12 (12.9) 20

7 (7.5) 12

3 (3.2) 3

Gastrointestinal disorders

37 (37.8) 62

55 (57.9) 101

58 (64.4) 121

66 (71.0) 157

72 (77.4) 167

60 (63.2) 110

 Abdominal pain

4 (4.1) 4

2 (2.1) 2

3 (3.3) 3

1 (1.1) 1

5 (5.4) 5

4 (4.2) 5

 Abdominal pain upper

1 (1.0) 1

5 (5.3) 6

2 (2.2) 3

5 (5.4) 5

5 (5.4) 7

7 (7.4) 8

 Constipation

12 (12.2) 14

15 (15.8) 17

11 (12.2) 12

21 (22.6) 24

17 (18.3) 18

7 (7.4) 8

 Diarrhea

10 (10.2) 11

8 (8.4) 13

9 (10.0) 12

12 (12.9) 13

14 (15.1) 15

28 (29.5) 40

 Dyspepsia

3 (3.1) 3

6 (6.3) 7

7 (7.8) 7

9 (9.7) 13

8 (8.6) 8

3 (3.2) 4

 Flatulence

1 (1.0) 1

4 (4.4) 4

4 (4.3) 4

3 (3.2) 3

10 (10.5) 10

 Nausea

7 (7.1) 8

23 (24.2) 27

29 (32.2) 33

35 (37.6) 48

45 (48.4) 68

7 (7.4) 7

 Steatorrhea

5 (5.3) 5

 Toothache

1 (1.0) 1

1 (1.1) 1

5 (5.6) 7

1 (1.1) 1

1 (1.1) 1

 Vomiting

2 (2.0) 2

5 (5.3) 6

9 (10.0) 18

14 (15.1) 17

12 (12.9) 16

2 (2.1) 4

Psychiatric disorders

5 (5.1) 5

3 (3.2) 3

4 (4.4) 4

11 (11.8) 14

12 (12.9) 14

5 (5.3) 8

 Acute stress disorder

1 (1.1) 1

 Affect lability

1 (1.1) 1

 Alcohol abuse

1 (1.1) 1

 Anxiety

1 (1.0) 1

2 (2.2) 2

2 (2.2) 2

 Burnout syndrome

1 (1.1) 1

 Depressed mood

1 (1.1) 1

3 (3.2) 3

1 (1.1) 1

 Depression

2 (2.2) 2

2 (2.2) 2

1 (1.1) 1

2 (2.1) 3

 Eating disorder

1 (1.1) 1

 Food aversion

1 (1.1) 1

 Insomnia

2 (2.0) 2

2 (2.2) 2

5 (5.4) 6

2 (2.1) 3

 Mood altered

1 (1.1) 1

1 (1.1) 1

 Nervousness

2 (2.2) 2

 Restlessness

1 (1.1) 1

 Stress

2 (2.0) 2

1 (1.1) 1

1 (1.1) 1

2 (2.2) 2

  1. Abbreviations: AE, adverse event; E, number of adverse event; N (%), number and proportion of participants with an adverse event; SAE, serious adverse event.
  2. aDoes not include individuals who chose not to enroll in the extension period.